Skip to content

Artiva Biotherapeutics, Inc. ARTV Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Gilead Sciences logo
Gilead SciencesGILD
Allogene Therapeutics logo
Allogene TherapeuticsALLO
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s preferred stock, shares authorized?
Artiva Biotherapeutics, Inc. (ARTV) reported preferred stock, shares authorized of $10M in Q3 2024.